- Home
- TJGC vs CNTX Comparison
TJGC vs CNTX Comparison
Compare TJGC & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TJGC | CNTX |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 47.7M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TJGC | CNTX |
|---|---|---|
| Price | $10.51 | $0.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 1.7M | ★ 2.0M |
| Earning Date | 08-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.49 | $0.35 |
| 52 Week High | $10.80 | $3.62 |
Technical Indicators
Market Signals| Indicator | TJGC | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 83.78 | 29.84 |
| Support Level | $4.11 | N/A |
| Resistance Level | N/A | $0.70 |
| Average True Range (ATR) | 0.98 | 0.04 |
| MACD | 0.44 | 0.00 |
| Stochastic Oscillator | 94.73 | 11.61 |
Price Performance
Historical ComparisonAbout TJGC TJGC Group Limited Ordinary Shares
TJGC Group Ltd, formerly CTRL Group Ltd is an integrated marketing and advertising services provider in Hong Kong specializing in mobile games promotion for the local market. It provide services to mobile game developers, principally developers of mobile gaming applications or apps that gamers download from the developers' websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.